866-997-4948(US-Canada Toll Free)

Brain Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 169 Pages


Global Markets Directs, Brain Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Brain Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Brain Cancer.
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Brain Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Brain Cancer 9
Brain Cancer Therapeutics under Development by Companies 11
Brain Cancer Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Brain Cancer Therapeutics Products under Development by Companies 18
Brain Cancer Therapeutics Products under Investigation by Universities/Institutes 20
Companies Involved in Brain Cancer Therapeutics Development 21
F. Hoffmann-La Roche Ltd. 21
Antigenics, Inc. 22
Gilead Sciences, Inc. 23
CK Life Sciences Intl., (Holdings) Inc. 24
Dong-A Pharmaceutical Co., Ltd. 25
Cell Therapeutics, Inc. 26
Alfacell Corporation 27
Advaxis, Inc. 28
EpiCept Corporation 29
Neuralstem, Inc. 30
Basilea Pharmaceutica Ltd. 31
Bionomics Limited 32
Critical Outcome Technologies Inc. 33
Prana Biotechnology Limited 34
e-Therapeutics plc 35
Nanobiotix 36
Spectrum Pharmaceuticals, Inc. 37
Philogen S.p.A. 38
AngioChem Inc. 39
Hawthorn Pharmaceuticals, Inc. 40
Diffusion Pharmaceuticals LLC 41
Stemline Therapeutics, Inc. 42
TVAX Biomedical, LLC 43
Kinex Pharmaceuticals, LLC 44
to-BBB technologies BV 45
Archer Biosciences, Inc 46
DEKK-TEC, Inc. 47
TAU Therapeutics, LLC 48
Brain Cancer Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
neratinib - Drug Profile 55
paclitaxel poliglumex - Drug Profile 59
verubulin - Drug Profile 63
COTI-2 - Drug Profile 66
lucanthone hydrochloride - Drug Profile 69
BAL-27862 - Drug Profile 71
AC 03-636 - Drug Profile 72
SL-302 - Drug Profile 73
SL-301 - Drug Profile 74
DA-3607 - Drug Profile 75
2,5-dimethyl celecoxib - Drug Profile 76
ADXS-HER2 - Drug Profile 77
BNC-105 - Drug Profile 78
ETS-2101 - Drug Profile 80
veliparib - Drug Profile 82
ARC-100 - Drug Profile 84
ANG-1007 - Drug Profile 86
DM-CHOC-PEN - Drug Profile 87
TVI-Brain-1 - Drug Profile 88
nimotuzumab - Drug Profile 90
EGEN-001 - Drug Profile 93
ANG-1009 - Drug Profile 95
TTL-1177 - Drug Profile 96
CFAK-C4 - Drug Profile 97
trastuzumab - Drug Profile 99
NSI-566RSC - Drug Profile 101
radretumab - Drug Profile 103
KX-02 - Drug Profile 105
CFAK-Y15 - Drug Profile 106
PBT-519 - Drug Profile 107
BT-2111 - Drug Profile 108
pritumumab - Drug Profile 109
JRP-890 - Drug Profile 111
JRP-980 - Drug Profile 112
Drug For Glioblastoma And Brain Metastatized Systemic Cancers - Drug Profile 113
STE-301 - Drug Profile 114
STE-401 - Drug Profile 115
Cancer Vaccine + CpG + Lysate - Drug Profile 116
Granulin Related Molecules - Drug Profile 117
Triaryl NADPH Oxidase Inhibitor - Drug Profile 118
ANG-4043 - Drug Profile 119
STE-101 - Drug Profile 120
Brain Cancer Program - Drug Profile 121
ONC-201 - Drug Profile 122
G-200 - Drug Profile 123
CKBP-002 - Drug Profile 125
NBTX-IV - Drug Profile 126
Brain Cancer Program - Drug Profile 127
Brain Cancer Therapeutics Drug Profile Updates 128
Brain Cancer Therapeutics Discontinued Products 155
Brain Cancer Therapeutics - Dormant Products 156
Brain Cancer Product Development Milestones 158
Featured News & Press Releases 158

Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 166
Disclaimer 166

List of Table


Number of Products Under Development for Brain Cancer, H2 2013 12
Products under Development for Brain Cancer Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 17
Comparative Analysis by Mid Clinical Stage Development, H2 2013 18
Comparative Analysis by Early Clinical Stage Development, H2 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Development by Companies, H2 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2013 23
F. Hoffmann-La Roche Ltd., H2 2013 24
Antigenics, Inc., H2 2013 25
Gilead Sciences, Inc., H2 2013 26
CK Life Sciences Intl., (Holdings) Inc., H2 2013 27
Dong-A Pharmaceutical Co., Ltd., H2 2013 28
Cell Therapeutics, Inc., H2 2013 29
Alfacell Corporation, H2 2013 30
Advaxis, Inc., H2 2013 31
EpiCept Corporation, H2 2013 32
Neuralstem, Inc., H2 2013 33
Basilea Pharmaceutica Ltd., H2 2013 34
Bionomics Limited, H2 2013 35
Critical Outcome Technologies Inc., H2 2013 36
Prana Biotechnology Limited, H2 2013 37
e-Therapeutics plc, H2 2013 38
Nanobiotix, H2 2013 39
Spectrum Pharmaceuticals, Inc., H2 2013 40
Philogen S.p.A., H2 2013 41
AngioChem Inc., H2 2013 42
Hawthorn Pharmaceuticals, Inc., H2 2013 43
Stemline Therapeutics, Inc., H2 2013 45
TVAX Biomedical, LLC, H2 2013 46
Kinex Pharmaceuticals, LLC, H2 2013 47
Archer Biosciences, Inc, H2 2013 49
DEKK-TEC, Inc., H2 2013 50
TAU Therapeutics, LLC, H2 2013 51
Assessment by Monotherapy Products, H2 2013 52
Assessment by Combination Products, H2 2013 53
Assessment by Stage and Route of Administration, H2 2013 55
Assessment by Stage and Molecule Type, H2 2013 57
Brain Cancer Therapeutics Drug Profile Updates 131
Brain Cancer Therapeutics Discontinued Products 158
Brain Cancer Therapeutics Dormant Products 159
Brain Cancer Therapeutics Dormant Products (Contd..1) 160

List of Chart


Number of Products under Development for Brain Cancer, H2 2013 12
Products under Development for Brain Cancer Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Mid Clinical Stage Products, H2 2013 18
Early Clinical Stage Products, H2 2013 19
Discovery and Pre-Clinical Stage Products, H2 2013 20
Assessment by Monotherapy Products, H2 2013 52
Assessment by Combination Products, H2 2013 53
Assessment by Route of Administration, H2 2013 54
Assessment by Stage and Route of Administration, H2 2013 55
Assessment by Molecule Type, H2 2013 56
Assessment by Stage and Molecule Type, H2 2013 57

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *